RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000131.xml
Synfacts 2010(5): 0506-0506
DOI: 10.1055/s-0029-1219649
DOI: 10.1055/s-0029-1219649
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag
Stuttgart ˙ New York
Synthesis of (R)-Olodaterol
T. Bouyssou, C. Hoenke, K. Rudolf, P. Lustenberger, S. Pestel, P. Sieger, R. Lotz, C. Heine, F. H. Büttner, A. Schnapp, I. Konetzki*
Boehringer Ingelheim Pharma GmbH & Co., Biberach, Germany
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
22. April 2010 (online)
![](https://www.thieme-connect.de/media/synfacts/201005/lookinside/thumbnails/10.1055-s-0029-1219649-1.jpg)
Significance
Olodaterol is a potent agonist of the human β2-adrenoceptor with a high β1/β2 selectivity. Its crystalline hydrochloride salt is suitable for inhalation and is currently undergoing clinical trials in man for the treatment of asthma. Olodaterol has a duration of action that exceeds 24 hours in two preclinical animal models of bronchoprotection and it has a better safety margin compared with formoterol.